Article Type
Changed
Tue, 02/07/2023 - 16:42

Key clinical point: Patients with psoriatic arthritis (PsA) have high anxiety levels before initiating biologics, which decreased within 6 months thereafter and was tied with better patient outcomes.

Major finding: Overall, 64% of patients had high anxiety levels before initiating biologics, with the proportion of patients with high anxiety levels and mean anxiety scores decreasing significantly within 6 months of initiating biologics (both P < .001). A change in anxiety score correlated positively with a change in pain score, patient global assessment score, Bath Ankylosing Spondylitis Disease Activity Index, Health Assessment Questionnaire-Disability Index score, Disease Activity Score-28, and PsA Impact of Disease score (all P < .05).

Study details: Findings are from an analysis of 147 patients with PsA who initiated  biologic agents and had an anxiety score assessed at both baseline and first visit within 6 months.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Ayan G et al. Clin Rheumatol. 2022 (Jan 27). Doi: 10.1007/s10067-021-06012-y.

Publications
Topics
Sections

Key clinical point: Patients with psoriatic arthritis (PsA) have high anxiety levels before initiating biologics, which decreased within 6 months thereafter and was tied with better patient outcomes.

Major finding: Overall, 64% of patients had high anxiety levels before initiating biologics, with the proportion of patients with high anxiety levels and mean anxiety scores decreasing significantly within 6 months of initiating biologics (both P < .001). A change in anxiety score correlated positively with a change in pain score, patient global assessment score, Bath Ankylosing Spondylitis Disease Activity Index, Health Assessment Questionnaire-Disability Index score, Disease Activity Score-28, and PsA Impact of Disease score (all P < .05).

Study details: Findings are from an analysis of 147 patients with PsA who initiated  biologic agents and had an anxiety score assessed at both baseline and first visit within 6 months.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Ayan G et al. Clin Rheumatol. 2022 (Jan 27). Doi: 10.1007/s10067-021-06012-y.

Key clinical point: Patients with psoriatic arthritis (PsA) have high anxiety levels before initiating biologics, which decreased within 6 months thereafter and was tied with better patient outcomes.

Major finding: Overall, 64% of patients had high anxiety levels before initiating biologics, with the proportion of patients with high anxiety levels and mean anxiety scores decreasing significantly within 6 months of initiating biologics (both P < .001). A change in anxiety score correlated positively with a change in pain score, patient global assessment score, Bath Ankylosing Spondylitis Disease Activity Index, Health Assessment Questionnaire-Disability Index score, Disease Activity Score-28, and PsA Impact of Disease score (all P < .05).

Study details: Findings are from an analysis of 147 patients with PsA who initiated  biologic agents and had an anxiety score assessed at both baseline and first visit within 6 months.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Ayan G et al. Clin Rheumatol. 2022 (Jan 27). Doi: 10.1007/s10067-021-06012-y.

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: PsA March 2022
Gate On Date
Wed, 02/23/2022 - 18:00
Un-Gate On Date
Wed, 02/23/2022 - 18:00
Use ProPublica
CFC Schedule Remove Status
Wed, 02/23/2022 - 18:00
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article